HKU Technology Transfer, Spin-offs and the Startup Ecosystem

The University of Hong Kong (HKU) comprehensive information database · Module 04 — Research This article traces how HKU turns research into industry: the Technology Transfer Office (TTO) / Versitech, startup incubation (iDendron, TSSSU@HKU), and patents and spin-off/startup companies. For named companies, this archive only includes those where we can verify a genuine technological or personnel link to HKU, so as to avoid mistaking "registered in Hong Kong" for "spun off from HKU."

---

# 1. The technology transfer system: TTO and Versitech

HKU's technology transfer is coordinated by the Technology Transfer Office (TTO), with commercialisation carried out by Versitech Limited — HKU's wholly-owned subsidiary responsible for intellectual property management, licensing, and equity stakes in spin-off companies. According to Versitech's startup page^※, the TTO/Versitech drives the commercialisation of HKU research and participates as a shareholder in a number of spin-offs.

Versitech is not a recent creation. According to Versitech's "About Us" page^※, it was established in 1994, registered as a non-profit company with a board that has long included business figures. It negotiates, signs, and manages commercial contracts on behalf of HKU, taking inventions to market via one of three routes — licensing, founding a startup, or collaboration — while also undertaking contract research and consultancy in partnership with HKU researchers. In other words, academics dealing with industry do not have to act as their own negotiators and legal counsel; this whole "university-against-company" interface has been handled by Versitech for nearly three decades.

A concrete example: according to HKU press release^※, the patented HKU technology "Flow-through hybridization" has been widely adopted by a biotechnology company (Hybribio) in its nucleic acid testing product lines. The company later listed on the Growth Enterprise Market (GEM), and Versitech is one of its shareholders. This chain illustrates the "licensing" model clearly: HKU does not need to manufacture test reagents itself or open factories; it simply licenses a core patented method to a company with production capacity and distribution channels, then shares in that company's growth as a shareholder. The academic's invention thus enters the capital market while the University's operational risk is kept to a minimum. This is a textbook example of the "licence to others" route in HKU's patent commercialisation — the polar opposite of the "found a company ourselves" route embodied by Momentus, discussed later in this article.

Why does this layer matter? If a university's inventions stop at papers and patents, industry cannot readily adopt them. Versitech's role is to convert research output into licensing contracts and equity that industry can sign, sparing academics the need to handle IP negotiations, company registration, and financing structures themselves. According to Versitech's startup page^※, its business covers both outward licensing and inward equity holding: it licenses individual technologies to established companies (as in the Hybribio case above) and also accompanies spin-offs as a founding shareholder from the laboratory to the market. These two routes — "licence to others" and "found a company" — form the two main themes of the rest of this article.

One often-overlooked institutional backdrop is the source of funding. Much of HKU's startup funding is not shouldered by the University alone but taps into the University Technology Start-up Support Scheme (TSSSU) run by the Innovation and Technology Commission (ITC) for six local universities: according to Versitech's funding page^※, the ITC allocates up to approximately HK$16 million per university per year, which each university then distributes to its own startups. Understanding this explains where TSSSU@HKU's money comes from and why the figures across universities are comparable.

---

# 2. The coordinating hub: HKU TEC and the restructuring of the startup architecture

HKU's startup support is not a department; it is a network. In 2022, HKU established the Techno-Entrepreneurship Core (HKU TEC) as the hub coordinating startup resources university-wide, drawing the previously scattered incubation, funding, mentoring, and investment networks under one roof; iDendron was repositioned as its community and physical-space vehicle. According to the HKU TEC website^※, the areas TEC oversees include education and competitions, incubation and funding (the seed scheme, DeepTech100, TSSSU@HKU), mentorship, shared space, and an angel investment network.

By its own account on the HKU TEC website^※, TEC has supported more than 500 startups, over 14,000 participants, and more than 350 ecosystem partners, providing over 1,500 hours of mentoring each year. iDendron has likewise expanded from a single campus site to three locations: iDendron@HKU (on campus), iDendron@Wan Chai, and iDendron@Qianhai — the last of these extending incubation reach into Shenzhen's Qianhai (on the Shenzhen–Hong Kong synergy, see Section 5 below).

On the funding side, HKU has in recent years set up a two-tier fund structure: according to HKU's 2024 annual report^※, the Entrepreneurship Engine Fund targets raising more than HK$400 million for high-potential HKU spin-offs; according to HKU's Knowledge Exchange Office^※, TEC has also set up the Gobi-HKU Fund I jointly with venture capital firm Gobi Partners, paired with a venture mentoring service. This marks HKU's shift from "incubation plus a bit of seed money" towards institutionalised venture capital (further progress in Section 5).

How big had this network grown by the 2024–25 academic year? According to HKU's 2025 annual report, technology transfer section^※, that year HKU had a cumulative total of 445 active startups, of which 65 were based at the Qianhai Techno-Entrepreneurship Academy (HKU TEA); the University's SEED Programme generated a further 41 tech startups. On the entrepreneurship education side, the Entrepreneurship Academy attracted more than 1,400 participant-visits, and Innovation Wing activities drew over 3,000; the University also fielded teams for the 2024 GenAI Hackathon for Social Good, with 71 teams entering. These figures should not be added to the programme-level counts elsewhere in this article (TSSSU numbers, DeepTech100 numbers, iDendron numbers): the 445 figure is HKU's annual total for "active startups," while the programme counts are subsets of those 445 that passed through particular funding or incubation schemes. For an overview of HKU's overall research intensity and competitive funding scale, see Research Output Overview.

---

# 3. Startup incubation: iDendron and TSSSU@HKU

# 3.1 The iDendron innovation and entrepreneurship hub

According to an HKU press release^※, HKU's innovation and entrepreneurship hub iDendron was launched on 23 October 2017 on the first floor of the Knowles Building, funded by the Azalea (1972) Endowment Fund, with support from Sino Group, Stanley Chu, and others, and with strategic partners including the Hong Kong Science and Technology Parks Corporation, Cyberport, and HK X-Tech Startup Platform. At launch, 20 startup teams led by HKU students and young alumni moved in; flagship programmes included DreamCatchers and the Entrepreneurship Academy. iDendron is supported and operated by the TTO.

# 3.2 TSSSU@HKU and incubation programmes

According to an HKU TTO news item^※:

• The University Technology Start-up Support Scheme (TSSSU@HKU) began in 2014; each startup may receive up to HK$1.5 million per year for a maximum of 3 years.
• In the year covered by that news item (2019/2020), 25 HKU startups received TSSSU@HKU funding; since 2014, TSSSU@HKU has supported 48 startups in total, of which 9 entered Cyberport and 15 joined related Science Park programmes.
• The iDendron Incubation Programme (iIP) lasts 6 months; the first cohort selected 12 early-stage startups, matched with 21 mentors (HKU academics, entrepreneurs, venture capitalists, and industry experts).

This is not a programme unique to HKU. According to the Innovation and Technology Fund's TSSSU page^※, TSSSU was established by the Innovation and Technology Commission (ITC) in 2014–15 under the Innovation and Technology Fund (ITF), aimed at six local universities and encouraging faculty and students to turn research output into startups — HKU's TSSSU@HKU is just one university's allocation window. Understanding this "government funds, universities allocate" structure is essential to seeing why the numbers across universities are comparable and why the cap is uniformly HK$1.5 million per startup per year.

Recent figures (multiple years side by side). The programme has expanded year on year. According to an HKU 2018 news item^※, 16 HKU startups received funding in 2018; according to an HKU TTO announcement^※, this rose to 32 in the 2023–24 financial year, with the funding cap split into two tiers — TSSSU-O and TSSSU+ — each still capped at HK$1.5 million per startup per year for up to 3 years. Placing the 16 of 2018, the 25 of 2019/2020, and the 32 of 2023–24 side by side shows a steady annual climb in the number of HKU-funded startups over several years, not a one-off spike.

In addition, from 2022 HKU launched DeepTech100, a deep-technology startup programme aimed specifically at "hard tech" projects requiring long development cycles and heavy R&D investment — the kind that do not fit the short rhythm of a typical accelerator. According to HKU's 2024 annual report^※, since 2022 DeepTech100 has supported 81 research-based deep-tech startups, each receiving up to roughly HK$1.39 million; the same annual report discloses that the first cohort of the Techno-Entrepreneurship Academy took in 11 startups, and that students on iDendron programmes founded 36 new companies in 2023–24. Stack these numbers together: TSSSU looks after "government-funded startups," DeepTech100 after "R&D-heavy deep tech," the Academy after "systematic entrepreneurship training," and iDendron after "campus community and student startups" — four tracks, each with its own remit, running in parallel. That is the most distinctive feature of HKU's startup architecture since the 2022 reorganisation, and the concrete knitting of the "network" described in Section 2.

DeepTech100 later became DeepTech100+, handing the definition of "deep tech" to an outside partner to police jointly. According to the HKU TEC "DeepTech100+" website^※, the programme is now co-organised by iDendron and the Hong Kong Science and Technology Parks Corporation (HKSTP) — the first programme in Hong Kong dedicated to converting university deep-tech research into future companies. It recruits twice a year (application deadlines fixed on the last Sundays of May and November), offers an incubation package worth up to about HK$1.4 million, and provides priority access to TSSSU@HKU cash funding of up to HK$1.5 million, plus customised support on IP strategy, team formation, industry networking, and fundraising. As of the second half of 2025, the programme had rolled to its sixth cohort — putting the "brand-new scheme" of 2022 next to the "six cohorts on a rolling basis, with an upgraded co-organiser" of three years later makes clear that this deep-tech track itself keeps iterating, rather than being a one-off launch.

---

# 4. Spin-off / startup companies (verifiable cases)

According to Versitech's "HKU Startup / Spin-off Companies" page^※, HKU's spin-offs and startups span biomedicine, robotics, marine technology, health technology, and more. Selected highlights (all from that official page):

What these names share is "hard technology in the lab first, company second." Biomedicine is the largest group: OncoSeek uses circulating tumour cells for early screening of aggressive cancers, AlhenaBio uses aptamers for digital diagnostics, Living Tissues works on cartilage regeneration — all derived from existing HKU research in medicine and life sciences. Robotics and marine technology extend HKU's strengths in engineering and science: Momentus's MR-safe hydraulic motors, Clear Robotics's marine IoT sensing, archiREEF's 3D-printed reef tiles each occupy their own niche. Then there are applied software projects like Hollo (an AI mental health platform) and AI Academy (AI education). Three cases are examined in detail below, corresponding to three distinct commercialisation routes: "licensing/listing," "cross-border commercialisation," and "building a deep-tech company in-house."

# 4.1 Case study: Novoheart's "heart in a jar" and its subsequent capital journey

From a laboratory device to cross-market listing, Novoheart is the HKU spin-off that has travelled furthest. According to multiple reports, its founder Professor Ronald Li (李登伟) was an HKU chair professor and centre director in stem cell and regenerative medicine; Novoheart used stem cells and bioengineering to create a thumb-sized human "heart-in-a-jar" model that contracts and "pumps" — the company calls it a "human ventricular cardiac organoid chamber (hvCOC)" — capable of generating pressure, ejecting fluid, and conducting electrical signals, for use in preclinical drug testing. According to Novoheart's official introduction^※, this "human heart-in-a-jar" is described as the only platform of its kind in the industry. The early core team also had HKU backgrounds — the chief operating officer, for instance, had previously served as deputy director of core facilities at HKU's medical faculty before joining.

The company's capital trajectory is especially instructive about how a "HKU spin-off" makes its way to the public markets. According to Novoheart's reverse takeover announcement^※, Novoheart listed on the Toronto Venture Exchange (TSX-V) in 2017 via a reverse takeover, with a simultaneous dual listing on the Frankfurt Stock Exchange; in 2020 it was acquired and taken private by biopharmaceutical group Medera, becoming its preclinical business unit. According to a PRNewswire report^※, in September 2024 Medera signed a merger agreement with special purpose acquisition company Keen Vision Acquisition Corporation (NASDAQ: KVAC), intending to reach Nasdaq through a reverse merger; according to an Ainvest report^※, the transaction valued Medera at more than US$600 million. A "pumping glass jar" that began in an HKU stem cell laboratory ended up as the technological foundation of a cross-market listed biopharmaceutical company — a remarkably complete loop in HKU's research commercialisation chain.

# 4.2 Case study: archiREEF — from Hoi Ha Wan, Sai Kung, to Abu Dhabi

archiREEF is a spin-off incubated at the intersection of HKU architecture and marine science; co-founder Vriko Yu (余碧珊) was a HKU biosciences PhD student. According to an HKU press release^※, HKU's Faculty of Architecture and marine scientists jointly developed a 3D-printed "reef tile" to which corals can attach, raising their survival rate, piloted in the Hoi Ha Wan Marine Park in Sai Kung — an initial batch of 128 tiles about 600 mm in diameter, 3D-printed in clay by robotic arm and fired at roughly 1,125°C. According to multiple reports, the team incorporated archiREEF in 2020 to commercialise the technology.

It then became one of the few HKU spin-offs to "go abroad." According to an SCMP report^※, archiREEF received investment in 2022 from Abu Dhabi sovereign fund ADQ and set up a local facility, building a factory in the KEZAD economic zone to produce 3D-printed terracotta reef tiles; according to the Abu Dhabi Government Media Office^※, the company, ADQ, and the Abu Dhabi Environment Agency deployed roughly 40 square metres of reef tiles in a marine protected area near Um Khorah Island, carrying approximately 1,200 coral fragments. The company reports cumulative restoration of about 500 square metres of marine habitat across Hong Kong and Abu Dhabi. In HKU's "research–incubation–commercialisation" chain, this was the first time a laboratory tile of clay made in Hong Kong was sold to the Arabian Gulf.

# 4.3 Case study: Momentus Robotics — sending robots into the MRI magnet

How do you make a robot move inside a strong magnetic field without disrupting imaging? That is the engineering puzzle Momentus Robotics set out to solve. According to Versitech news^※, the company stems from the team of Ka-Wai Kwok (郭嘉威), a HKU mechanical engineering academic; its patented technology is a low-friction hydraulic transmission system that transfers power via fluid between the MRI suite and the control room — over distances of up to about 10 metres — and contains no metal parts at all: it is "MR-safe," able to operate safely in the magnetic resonance environment without degrading image quality. The team has applied the technology to more than four MRI-guided surgical projects, including cardiac catheter intervention and functional stereotactic neurosurgery. According to the same news item, the company received TSSSU@HKU 2022/23 funding and joined the Hong Kong Science Park's Incu-Tech programme. This is the classic "found a company around a deep-tech patent" rather than "licence it to others" route — a direct counterpoint to the Hybribio licensing model above.

# 4.4 Case study: SewingDX — turning "sewing" into a robotics problem

Why is sewing a garment harder to automate than building a car? Because fabric is soft and deformable, making it difficult for conventional robotic arms to grip and position reliably — and this is precisely the problem addressed by the Centre for Transformative Garment Production (TransGP). According to China Daily Hong Kong^※, TransGP was jointly established in 2020 by HKU and Japan's Tohoku University under the InnoHK framework, with HKU engineering academic Norman Tien (田址), a chair professor, serving as managing director. The centre focuses on three directions: "fixture-free sewing," automated garment material handling, and human–robot collaboration.

The centre has since incubated three spin-offs with distinct focuses: SewingDX (2D/3D automated sewing systems), PALGRIP (robotic gripping and fabric positioning), and FlexAI (machine-vision-based motion analysis and object recognition for AI manufacturing). According to the SewingDX website^※, its system can sew flat fabric panels directly into three-dimensional shapes; in 2025 the technology was named by industry media StartUs Insights as one of the "top ten emerging garment manufacturing technologies for 2025 and beyond," the only entry on the list from outside the US, UK, or Europe, attracting attention from both the garment and automotive industries. This case widens the "spin-off" family tree one step further: Novoheart, archiREEF, and Momentus all stem from patents held in HKU's own faculties, whereas SewingDX comes out of a joint research centre that HKU built with an overseas university, funded by the government's InnoHK programme — the technological origins of HKU spin-offs are not limited to a single in-house laboratory.

# 4.5 Student startup seed fund: DreamCatchers

According to iDendron / DreamCatchers materials^※, HKU launched the student startup seed fund DreamCatchers 100K in 2016 to support students and young graduates getting started; winning teams receive up to HK$100,000 in cash plus iDendron shared-space memberships. In 2018, for example, the DreamCatchers 100K finals were held on 15 April, awarding four prizes of HK$100,000, four of HK$50,000, and free iDendron memberships. DreamCatchers, the MedTech Hackathon, and the Entrepreneurship Academy are iDendron's flagship incubation programmes. The student track and the professor-led deep-tech spin-offs described above operate on different levels: the former builds entrepreneurial habits and teams, with most ventures still early-stage; the latter commercialises mature patents — the two tracks run in parallel under the same iDendron roof.

# 4.6 Case study: Digitoe's "iWalk" — an external test for the student track

University seed funds provide starting capital; the real test of a team's mettle usually comes from external competitions. According to a Media OutReach report^※, the "Samsung Solve for Tomorrow 2024–25" competition, themed "shaping future pathways with AI," saw entries nearly double year on year to about 500 teams (from 180 institutions), ran for eight months, and concluded on 14 April 2025. The HKU student team Digitoe took the top prize in the tertiary category with "iWalk" — a project combining smart insoles (capturing gait data, customising orthotic insoles) with a companion mobile app that helps podiatrists monitor children's foot health and intervene early on posture problems; another HKU team received a merit award for "SCOLIOTRACK" (a scoliosis monitoring tool). This student-track output dovetails with the DreamCatchers 100K seed funding above: the university fund gives a team start-up money and shared space; the external competition provides a validation that HKU does not judge itself.

---

# 5. Shenzhen–Hong Kong synergy: Qianhai, the Greater Bay Area, and "patient capital"

In recent years HKU has pressed half the weight of its startup architecture north of the Shenzhen River. Besides iDendron@HKU on campus and the Wan Chai site, HKU has set up an iDendron@Qianhai office in Shenzhen's Qianhai and, jointly with the Qianhai Authority, the HKU Techno-Entrepreneurship Academy (HKU TEA). According to the HKU TEC Qianhai page^※, the office is located in the Qianhai Shenzhen–Hong Kong Youth Innovation and Entrepreneurship Hub; according to HKU TEA's first-anniversary review^※, HKU TEA was founded under a strategic cooperation agreement signed by HKU and the Qianhai Authority in 2022, incubating 67 high-tech startups in its first year, led by 18 distinguished professors and 40 PhDs, with nearly 300 young entrepreneurs participating (115 of them from Hong Kong), focused on artificial intelligence, biomedicine, and new materials. This twin-city path of "registered in Shenzhen, researched in Hong Kong" dovetails with HKU's wider research footprint in Shenzhen (the Shenzhen Research Institute, Shenzhen–Hong Kong collaboration platforms); see the research institutes chapter.

On the funding side, HKU has pushed its role further from "incubation plus a little seed money" towards institutionalised venture capital. According to an HKU news item^※, the Entrepreneurship Engine Fund (EEF) has received pledges of more than HK$370 million from top investors; according to HKU's Knowledge Exchange Office^※, the EEF has set up the Gobi-HKU Fund I (a fund-of-funds structure) with venture capital firm Gobi Partners, and launched a Venture Mentoring Service modelled on MIT and backed by the "HKU Super Angel Network" — reportedly the first mentoring programme in Hong Kong formally plugged into the MIT VMS network. According to an HKU press release^※, the first announced investments from Gobi-HKU Fund I at first close included Manifold Tech (robotic spatial intelligence) and AilsynBio (AI drug design). HKU sums up this approach as "patient capital": not chasing short-term returns but staying with research-based startups for the long haul. This also explains why Section 2 said startup support "is not a department; it is a network" — one end of the network is the campus incubation space; the other now extends to cross-border funds and sovereign capital.

This capital line went a step further in the first half of 2026. According to a press release from Hong Kong Investment Corporation Limited (HKIC)^※, Gobi-HKU Fund I formally reached its first close in March 2026, with the HKIC — the Hong Kong SAR government's sovereign-level investment platform — joining HKU and Gobi Partners as a participating investor. The first two investments completed were, as noted above, Manifold Tech and AilsynBio. This means the sources of capital for HKU-affiliated startups have moved from the original university seed funding, through cross-border VC joint ventures, to co-investment from the SAR government's sovereign capital platform — a three-tier funding ladder corresponding to the "start-up," "growth," and "scale-up" stages of a startup. Separately, according to HKU's 2025 annual report^※, the EEF's first investors pledged HK$370 million in December 2024, after which the University Council raised the EEF's long-term fundraising target to HK$1 billion; the associated HKU Super Angel Network was formally launched in March 2025, opening direct investment and mentoring channels in HKU startups to alumni. Laying the first pledges of December 2024, the Super Angel Network of March 2025, and the first close of Gobi-HKU Fund I (bringing in HKIC) of March 2026 in chronological order shows this capital network being assembled in three steps over roughly fifteen months — not announced all at once.

---

# 6. The test beyond the campus: the International Exhibition of Inventions Geneva

Beyond patents and startup registrations, there is a more direct form of "peer review" — taking inventions to an international exhibition to compete on the same stage with teams from around the world. According to HKU's 2025 annual report^※, the HKU delegation won 34 awards at the 50th International Exhibition of Inventions Geneva held in April 2025, including 1 Special Grand Prize and two gold medals for a technology developed by an HKU team related to a nasal spray influenza vaccine — nasal spray vaccines require no injection and are easier to administer, an emerging direction in vaccine delivery in recent years. This area continues HKU's long-standing strengths in infectious diseases and virology; see HKU's named pathogens and virology breakthroughs and signature virology and infection research.

Geneva is one of the world's largest invention exhibitions, with exhibitors from universities, companies, and independent inventors across dozens of countries and regions, and awards decided on site by an international jury — unlike internal counts such as "number of patents licensed," it offers an external, cross-border, same-stage signal. Thirty-four awards and one Special Grand Prize indicate that HKU's technological output does not stop at patent certificates and company registration lists, but continues to earn on-the-spot recognition from international peers.

---

# 7. Patents and intellectual property

HKU patents are licensed to industry through Versitech (as with the "flow-through hybridization" technology above), or commercialised by academics founding companies themselves (as with Momentus Robotics' hydraulic transmission patent). In terms of scale, by HKU's official account, cumulative patent applications related to HKU discoveries have reached approximately 1,900 — a figure that supplies the upstream annotation for the spin-off list: those that actually become companies are only a small fraction, filtered through licensing and financing. Year-by-year aggregates of HKU's patent applications/grants and licensing income are scattered across annual reports and TTO/Versitech disclosures; this archive has not obtained a single authoritative annual total and marks it not found (for a financial overview see ../08-finances/; for overall research output and competitive funding see Research Output Overview).

---

# 8. Summary and not-found items

• Securely sourced: TTO/Versitech mechanism; HKU TEC coordinating structure; iDendron (2017, Knowles Building, Azalea Fund); TSSSU@HKU (from 2014; HK$1.5M/year for 3 years; 25 in 2019/2020; 32 in 2023–24); DeepTech100+ (co-organised with HKSTP, rolled to Cohort 6); the spin-off list (Versitech's official page); the flow-through hybridization patent case; HKU TEA in Qianhai; 34 awards at the International Exhibition of Inventions Geneva — all supported by official HKU pages or mainstream media.
• Representative cases with complete chains: Novoheart → Medera's reverse merger aiming at Nasdaq (valuation over US$600 million); archiREEF's expansion to Abu Dhabi; Momentus Robotics' MR-safe hydraulic patent; SewingDX and sister companies PALGRIP/FlexAI from the HKU–Tohoku University joint centre — four cases corresponding respectively to the "licensing/listing," "cross-border commercialisation," "founding a company," and "transnational joint research centre incubation" routes.
• Capital network in three tiers: EEF first pledges (Dec 2024, HK$370 million) → Super Angel Network launch (Mar 2025) → Gobi-HKU Fund I first close bringing in HKIC (Mar 2026), in chronological order showing the evolution of HKU startup capital from university seed money to sovereign co-investment.
• Boundaries actively drawn: Insilico Medicine is not counted as an HKU spin-off (registered in Hong Kong only, not an institutional spin-off); claims such as Novoheart's "industry-only heart-in-a-jar" and Medera's valuation follow company's own statements or media attribution, not independent verification by this archive.
• Not found / left for other chapters: a single authoritative total for HKU's annual patent applications/grants and licensing income (not found; see the financial module ../08-finances/); the complete spin-off list with valuations/listing details, which follows Versitech's official page^※ and is not individually elaborated here; specific sizes of Gobi-HKU Fund I and the EEF, and the HKIC's share, for which no single authoritative figure has been disclosed — marked not found.

# Related reading

• HKU Research Institutes: State Key Laboratories, InnoHK and the Shenzhen Research Institute — HKU's research platforms in Shenzhen and the Greater Bay Area, counterpart to the Qianhai incubation covered here.
• HKU Research Output Overview: RAE, RGC funding, Nature Index — upstream research strength is the source water for downstream technology transfer.
• HKU Finances and Funding — financial scope of licensing income, endowment funds, and startup funds.
• HKU Named Pathogens and Virology Breakthroughs, Signature Virology and Infection Research — the upstream research behind the Geneva nasal spray influenza vaccine awards.

---